CN Patent

CN115667240B — Lnp023的结晶形式

Assigned to Novartis AG · Expires 2025-04-22 · 1y expired

What this patent protects

本文描述了LNP023盐酸盐的结晶水合物形式及其制备工艺。此外，本文描述了包含LNP023盐酸盐的结晶水合物形式和至少一种药学上可接受的赋形剂的药物组合物。本文所述的药物组合物可用于治疗由补体激活介导的疾病和障碍。

USPTO Abstract

本文描述了LNP023盐酸盐的结晶水合物形式及其制备工艺。此外，本文描述了包含LNP023盐酸盐的结晶水合物形式和至少一种药学上可接受的赋形剂的药物组合物。本文所述的药物组合物可用于治疗由补体激活介导的疾病和障碍。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN115667240B
Jurisdiction: CN
Classification: —
Expires: 2025-04-22
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.